Companies / Ocular Therapeutix, Inc

Ocular Therapeutix, Inc

Nasdaq: OCULCIK 1393434BEDFORD, MA

Financials · FY2025

Revenue$51.95M
Net income$-265.94M
Total debt$18.00M
Cash$598.64M
Diluted EPS$-1.42
Shares outstanding219.6M

Ownership

219.6M shares outstanding · as of Jul 31, 2026
2.9%Insiders
Ownership
Insiders2.88%6,315,211
10%+ / strategic4.20%9,234,132
Institutions78.73%172,894,163
Public float14.19%31,172,362

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 17

View all →
Insider% of sharesShares
Dugel PravinSee Remarks · Director
1.50%3,291,981
Notman DonaldChief Operating Officer
0.17%366,356
Nayak SanjayChief Strategy Officer
0.15%328,795
Heier Jeffrey S.Chief Scientific Officer
0.15%320,350
Waheed NadiaChief Medical Officer
0.14%300,079
Kaiser PeterChief Development Officer
0.12%266,141
0.12%260,933
Saroj NamrataChief Business Officer
0.12%254,620
Meyers Steve LawrenceChief Commercial Officer
0.10%217,628
Anderman ToddChief Legal Officer
0.07%152,468

Institutional holders 255

View all →
HolderValue% of shares
Fmr LLC$385.88M14.47%
BlackRock, Inc.$190.28M8.82%
Vanguard Group Inc$140.52M5.27%
Avoro Capital Advisors LLC$130.84M4.91%
Deep Track Capital, LP$97.97M3.67%
VR Adviser, LLC$88.81M3.33%
TCG Crossover Management, LLC$69.69M2.61%
Adage Capital Partners Gp, L.L.C.$56.15M2.11%
State Street Corporation$51.39M2.38%
AllianceBernstein L.P.$50.13M1.88%

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Adage Capital Partners Gp, L.L.C.
13F manager
Exit$-56.15M-4.6M
-100.00%
high
Q2 2026
as of
BlackRock, Inc.
13F manager
Add$37.06M+3.8M
+24.19%
19,376,555
8.82% of shares
medium
Q1 2026
as of
Janus Henderson Group PLC
13F manager
Trim$-35.26M-4.2M
-98.38%
68,500
0.03% of shares
medium
Q1 2026
as of
Millennium Management LLC
13F manager
Trim$-26.88M-3.2M
-98.94%
34,006
0.02% of shares
medium
Q1 2026
as of
Balyasny Asset Management L.P.
13F manager
Add$16.34M+1.9M
+252.64%
2,692,622
1.23% of shares
medium
Q1 2026
as of
Two Sigma Investments, LP
13F manager
Add$12.28M+1.4M
+380.72%
1,830,159
0.83% of shares
medium
Q2 2026
as of
State Street Corporation
13F manager
Add$10.18M+1.0M
+24.71%
5,233,282
2.38% of shares
medium
Q1 2026
as of
D. E. Shaw & Co., Inc.
13F manager
Trim$-7.92M-935K
-81.07%
218,478
0.10% of shares
medium

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A0
Deep Track Capital, LPPassive13G/A9,234,132
Venrock Healthcare Capital Partners III, L.P.Passive13G/A
Deep Track Capital, LPPassive13G11,234,132
Deep Track Capital, LPPassive13G/A20,850,000

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
OCUL67576A100